Company Information


CSL Limited (ASX: CSL)

CSL Limited is an Australian biotechnology company specializing in rare and serious diseases, influenza vaccines, and treatments for iron deficiency and nephrology. It comprises three main segments: CSL Behring, which focuses on plasma products, gene therapies, and recombinants; CSL Seqirus, dedicated to influenza vaccines and pandemic services; and CSL Vifor, which targets iron deficiency and nephrology therapeutics. The company also has a plasma collection network, CSL Plasma, with over 325 centers across the United States, Europe, and China.

Operating globally, with a presence in Australia, the United States, Germany, the UK, Switzerland, and China, CSL Limited offers products like Respreeza, Zemaira, HAEGARDA, KCENTRA, and Hepatitis B immunoglobulins, among others. Founded in 1991, the company has grown to employ over 32,000 people worldwide.

In financial terms, CSL Limited has reported a revenue of AUD 21.56 billion and a net income of AUD 3.76 billion. Despite significant revenue growth, the net income has changed little year on year, which can be attributed to increased costs of goods sold. The company’s stock is traded by major institutional holders such as The Vanguard Group, Inc., which owns 3.40% of the shares. For more information, interested parties can visit CSL Limited’s website.


Top Australian Brokers



CSL Limited (ASX: CSL) Live Chart


CSL Limited (ASX: CSL) Forecast

The consensus among eight Wall Street analysts is that the 12-month price target for CSL’s stock is AU$311.97. Predictions range from a low of AU$253.29 to a high of AU$338.50. This average target suggests a potential increase of 11.74% from the last recorded stock price of AU$279.20.


CSL Limited (ASX: CSL) Performance


CSL Limited (ASX: CSL) Fundamentals


CSL Limited (ASX: CSL) Competitors


Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2024.

We’re giving away this valuable research for FREE.

Click below to secure your copy